Hansa Biopharma AB (publ) (STO: HNSA)

Hansa Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	553.54	732.06	1,496	651.34	1,139	181.7
Short-Term Investments	-	-	-	237.62	238.14	419.4
Cash & Short-Term Investments	553.54	732.06	1,496	888.96	1,378	601.09
Cash Growth	-39.05%	-51.07%	68.31%	-35.47%	129.17%	-29.96%
Accounts Receivable	144.65	78.03	42.96	9.71	0.11	0.52
Other Receivables	45.49	15.73	24.22	13.53	7.59	4.73
Receivables	190.14	93.76	67.18	23.24	7.7	5.26
Inventory	1.98	1.51	0.97	0.24	0.1	-
Prepaid Expenses	-	3.06	3.52	3.34	1.66	2.66
Other Current Assets	-	24.76	36.85	26.56	6.43	6.74
Total Current Assets	745.66	855.15	1,605	942.34	1,393	615.74
Property, Plant & Equipment	20.18	27.07	35.84	41.71	9.7	15.14
Other Intangible Assets	174.84	23.17	26.01	28.76	31.41	33.35
Long-Term Deferred Charges	-	112.65	20.85	-	-	-
Total Assets	940.68	1,018	1,687	1,013	1,434	664.24
Accounts Payable	51.62	86.97	62.48	53.36	26.67	50.57
Accrued Expenses	90.78	116.54	100.32	78.22	52.36	31.69
Current Portion of Leases	7.61	7.5	7.17	6.89	4.42	4.63
Current Income Taxes Payable	1.12	1.6	0.6	-	0.13	0.32
Current Unearned Revenue	20.55	41.47	40.43	24.96	17.41	-
Other Current Liabilities	132.5	66.91	53.71	7.79	13.22	7.33
Total Current Liabilities	304.19	320.99	264.71	171.22	114.2	94.54
Long-Term Debt	942.95	844.9	762.6	-	-	-
Long-Term Leases	8.62	14.36	21.33	28.49	0.63	4.83
Long-Term Unearned Revenue	-	-	29.5	47.02	62.03	-
Long-Term Deferred Tax Liabilities	0.17	0.37	0.41	0.43	0.42	0.51
Other Long-Term Liabilities	4.7	5.3	5.95	8.08	15.09	1.55
Total Liabilities	1,261	1,186	1,084	255.24	192.37	101.42
Common Stock	-319.96	55.03	55.03	46.34	45.9	41.45
Additional Paid-In Capital	-	3,083	3,022	2,573	2,509	1,413
Retained Earnings	-	-3,303	-2,471	-1,860	-1,312	-971.82
Treasury Stock	-	-2.36	-2.59	-1.86	-1.42	-1.42
Comprehensive Income & Other	-	-0.41	0.01	0.13	-0.14	81.16
Shareholders' Equity	-319.96	-167.88	602.91	757.57	1,242	562.82
Total Liabilities & Equity	940.68	1,018	1,687	1,013	1,434	664.24
Total Debt	959.19	866.77	791.09	35.38	5.05	9.46
Net Cash (Debt)	-405.64	-134.71	705.09	853.58	1,372	591.64
Net Cash Growth	-	-	-17.40%	-37.81%	131.98%	-31.01%
Net Cash Per Share	-6.87	-2.56	15.70	19.19	32.54	14.78
Filing Date Shares Outstanding	67.81	52.67	52.44	44.47	44.47	40.03
Total Common Shares Outstanding	67.81	52.67	52.44	44.47	44.47	40.03
Working Capital	441.47	534.16	1,340	771.12	1,279	521.2
Book Value Per Share	-4.72	-3.19	11.50	17.03	27.93	14.06
Tangible Book Value	-494.8	-191.05	576.9	728.81	1,211	529.47
Tangible Book Value Per Share	-7.30	-3.63	11.00	16.39	27.22	13.23

Source: S&P Capital IQ. Standard template. Financial Sources.